On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

Single dose, single arm trial, exploring the initial 28 day safety and efficacy of the investigational drug.

Inclusion criteria

• Subjects voluntarily participate in clinical studies;
• ECOG score 0-1 points;
• Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and inert lymphoma transformed into diffuse large B-cell lymphoma; CD19 and/or CD20 positivity;
• At least one measurable tumor lesion determined according to Lugano's criteria: the longest diameter of intranodal lesions>1.5cm, and the longest diameter of extranodal lesions>1.0cm.

Exclusion criteria

• Received other chimeric antigen receptor therapy or gene modified cell therapy before screening;
• Subjects who were undergoing systemic steroid therapy during screening and were determined by the researchers to require long-term use of systemic steroid therapy during the treatment period (excluding inhalation or local use);
• Any unstable heart disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ III), and severe arrhythmia.